What happened with CATX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Perspective Therapeutics is a clinical-stage drug developer working on targeted alpha therapies—radioactive medicines intended to treat cancer. Its early clinical programs include VMT-α-NET for neuroendocrine tumors, VMT01 for metastatic melanoma and PSV359 for certain solid tumors. It sold its former brachytherapy business to GT Medical and now focuses on drug development.
The company has no approved drugs or sales from its current candidates. Its revenue comes from research work funded by the National Institutes of Health, while sales of equity to investors have historically supplied most of the cash needed to operate. It needs additional capital to continue development. Future drug sales depend on demonstrating safety and effectiveness, obtaining regulatory approval, and securing physician adoption and insurance reimbursement. It plans to rely on third-party collaborators for marketing and sales.
Producing doses for clinical trials also depends on a concentrated supply chain. Perspective obtains nearly all of its Thorium-228, the starting material used to produce lead-212, from the U.S. Department of Energy. It relies on single vendors for key generator components and for assembling and loading those generators, which extract lead-212 for trial doses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Perspective’s prospects hinge on clinical success and reliable Thorium-228 supply from the U.S. Department of Energy (DOE), while privately held Orano Med is an important alpha-radiopharmaceutical rival outside this list.
Aktis Oncology competes with Perspective to develop cancer drugs that deliver targeted alpha radiation; Perspective’s alpha therapies remain in clinical development rather than generating product sales. Watch Aktis’s research progress with Eli Lilly, which pays for the collaboration and takes over clinical development after initial human imaging studies.
Novartis already sells Lutathera for neuroendocrine tumors targeted by Perspective’s VMT-α-NET, giving Perspective an established treatment to compete against. Its development of drugs that deliver radiation to the tumor-associated FAP target also matters for Perspective’s competing FAP program.
Bristol Myers Squibb is developing radiation-delivering drugs for neuroendocrine tumors that compete with Perspective’s VMT-α-NET. For Perspective holders, progress in those programs matters more directly than Bristol Myers Squibb’s broader business selling medicines for serious diseases.
Immunome’s IM-3050 and Perspective’s FAP program could compete directly because both aim radiation-delivering drugs at the same tumor-associated target. Watch IM-3050’s clinical progress and access to radioactive-isotope supplies, which Immunome identifies as a competitive risk.
Lantheus develops competing cancer radiopharmaceuticals, but it also sold Perspective the Somerset, New Jersey manufacturing facility in March 2024. Lantheus sells products mainly to U.S. hospitals, imaging centers and government facilities; for Perspective, the acquired site’s three production suites are intended to supply drug product to the northeastern half of the United States.
Actinium and Perspective both depend on clinical validation of drugs that deliver radiation to cancer targets, though Actinium says their biological targets do not directly overlap. Actinium received payment from Immedica for regional rights to sell Iomab-B and may earn approval milestones and sales royalties, making Iomab-B’s progress a concrete development to follow without treating it as a direct substitute for Perspective’s drugs.
Cellectar and Perspective both need evidence that targeted radiation can treat cancer, but Cellectar uses phospholipid carriers to deliver radioactive isotopes while Perspective develops peptide-based drugs. Cellectar’s actinium-225 program CLR 225 is a concrete program to watch for progress in this treatment approach, not proof that Perspective’s own drugs work.
Telix develops therapeutic radiopharmaceuticals that compete with Perspective, but most of its revenue currently comes from prostate-cancer imaging agents rather than treatments. Its Illuccix and Gozellix sales through commercial and hospital radiopharmacies therefore tell a different story from progress in the therapeutic programs Perspective competes against.
Radiopharm Theranostics and Perspective both need successful trials and regulatory approvals before their isotope-linked cancer drugs can reach commercial use. Radiopharm has no products approved for sale, so its solid-tumor trial results—not product sales—are the relevant news to follow alongside Perspective’s clinical progress.
Monopar offers another test of targeted radiation treatment for cancer: it develops lutetium- and actinium-linked drugs for advanced solid tumors, while Perspective develops lead-212 alpha therapies. As of December 31, 2025, Monopar’s MNPR-101-Lu was in Phase 1a and MNPR-101-Ac was in late preclinical development, making those programs’ results more relevant to Perspective than its separate Wilson disease candidate.
Novartis AG earningsNVS
Novartis’s report can show whether its established Lutathera remains a formidable treatment in neuroendocrine tumors and offer clues on its FAP-targeted radiation drugs, both of which compete with Perspective Therapeutics programs.
Look for what Novartis says about Lutathera sales and further development in neuroendocrine tumors, and whether its FAP-targeted radiation programs advance. A strong Lutathera position means Perspective Therapeutics’ VMT-α-NET faces an established treatment; a weaker position could ease that competitive pressure, but would not establish VMT-α-NET’s effectiveness. Progress in Novartis’s FAP programs would add another competing approach for Perspective’s FAP program.
Immunome, Inc. earningsIMNM
Immunome’s report can show whether its FAP-targeted radiation drug IM-3050 is advancing clinically and whether radioactive-isotope supply is a constraint, relevant to Perspective Therapeutics’ competing FAP program.
Watch IM-3050’s clinical progress alongside Immunome’s comments on radioactive-isotope access. Clinical progress with reliable supply would show a rival advancing against Perspective Therapeutics on the shared FAP target; supply problems or delays would expose a constraint for Immunome, not prove Perspective has secure supply or an effective drug. The question is whether IM-3050 is becoming a more developed competitor in FAP-targeted treatment.
Perspective Therapeutics, Inc. earningsThis company
Perspective Therapeutics has no product-sale revenue from its drug candidates, so this report will show how clinical work is progressing alongside research spending and cash use.
Read clinical progress alongside cash used in operations and available cash. Progress with cash use consistent with the company’s funding plan would show that research spending is advancing clinical work while current milestones remain fundable. Faster cash use with limited progress would put that funding window under pressure and could force changes in program spending. The conclusion is whether Perspective Therapeutics can advance its trials within the time its resources can support.
